Showing 1 posts of 1 posts found.
The FDA’s Risk Evaluation and Mitigation Strategy (REMS), which began in 2012, failed to successfully police the companies creating opioids …
MHRA approves first lower-carbon beclometasone inhalers for asthma
Samsung Biologics launches bid to acquire peptide CDMO PolyPeptide
Novogenia breaks ground on personalised healthcare campus
InfectoPharm launches Polish operations with first hospital antibiotic
FibroFind appoints Lee Borthwick as CEO